Pazinib 400mg Tablet

Pazinib 400mg Tablet is a groundbreaking medication in the realm of oncology, offering renewed hope for patients battling various types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which work by inhibiting the action of specific proteins involved in cancer cell growth and proliferation. The active ingredient in Pazinib tablets is Pazopanib hydrochloride, meticulously formulated to target and disrupt the signaling pathways responsible for tumor progression.

Manufactured under stringent quality standards, Pazinib 400mg Tablet is available in oral dosage form, ensuring ease of administration for patients undergoing cancer therapy. Each tablet contains 400mg of Pazopanib, carefully calibrated to deliver optimal therapeutic efficacy while minimizing adverse effects.

USES of Pazinib 400mg Tablet

Pazinib 400mg Tablet is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer that has spread to other parts of the body. It is also approved for the management of soft tissue sarcoma (STS), a heterogeneous group of tumors arising from mesenchymal tissue, when other treatment options have been exhausted.

The versatility of Pazinib extends beyond these primary indications, with ongoing research exploring its efficacy in treating other malignancies, including ovarian cancer, non-small cell lung cancer, and thyroid cancer. As an oral medication, Pazinib offers the convenience of home-based therapy, allowing patients to maintain their quality of life while undergoing treatment.

BENEFITS OF Pazinib 400mg Tablet

• Effective Tumor Suppression: Pazinib exerts its antineoplastic effects by inhibiting the activity of multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. By targeting these key signaling pathways, Pazinib impedes tumor angiogenesis, growth, and metastasis, thereby arresting disease progression.
• Prolonged Progression-Free Survival: Clinical trials have demonstrated that Pazinib significantly prolongs progression-free survival (PFS) in patients with advanced RCC and STS compared to conventional chemotherapy or placebo. This translates to a meaningful extension of time without disease worsening, offering patients valuable time to spend with their loved ones and pursue meaningful activities.
• Well-Tolerated Oral Therapy: Unlike traditional intravenous chemotherapy, which often entails frequent hospital visits and debilitating side effects, Pazinib 400mg Tablet can be conveniently taken at home. Its favorable safety profile minimizes the risk of severe adverse reactions, enhancing treatment adherence and patient satisfaction.

SIDE EFFECTS OF Pazinib 400mg Tablet

While Pazinib is generally well-tolerated, like all medications, it may cause certain side effects. Common adverse reactions associated with Pazinib 400mg Tablet include:

• Fatigue: Patients may experience tiredness or weakness, which can impact daily activities. Adequate rest and gentle exercise can help alleviate fatigue.
• Hypertension: Pazinib may cause an elevation in blood pressure, requiring close monitoring and, in some cases, the initiation of antihypertensive therapy.
• Gastrointestinal Disturbances: Nausea, vomiting, diarrhea, and abdominal pain are among the most frequently reported gastrointestinal side effects of Pazinib. These symptoms can usually be managed with supportive care and dietary modifications.
• Liver Toxicity: Rarely, Pazinib may lead to liver function abnormalities, manifesting as elevated liver enzymes or jaundice. Regular liver function tests are recommended during treatment to monitor for hepatotoxicity.
• Hematologic Effects: Pazinib can suppress bone marrow function, resulting in decreased white blood cell count (neutropenia), platelet count (thrombocytopenia), or red blood cell count (anemia). Patients may be at increased risk of infections or bleeding and may require dose adjustments or supportive care interventions.

References